Exelixis (EXEL) Competitors

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Exelixis (NASDAQ:EXEL) are both large-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, community ranking, media sentiment, profitability, risk, dividends, earnings and institutional ownership.

Which has more risk and volatility, ALNY or EXEL?

Alnylam Pharmaceuticals has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500.

Which has preferable earnings & valuation, ALNY or EXEL?

Exelixis has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$2.35B	16.20	-$278.16M	-$2.09	-139.56
Exelixis	$2.30B	5.26	$521.27M	$2.20	20.16

Do institutionals & insiders hold more shares of ALNY or EXEL?

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 2.8% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Does the media favor ALNY or EXEL?

In the previous week, Exelixis had 30 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 50 mentions for Exelixis and 20 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 1.34 beat Exelixis' score of 0.75 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	14 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	24 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community favor ALNY or EXEL?

Alnylam Pharmaceuticals received 540 more outperform votes than Exelixis when rated by MarketBeat users. Likewise, 76.32% of users gave Alnylam Pharmaceuticals an outperform vote while only 68.60% of users gave Exelixis an outperform vote.

Company	Underperform	Outperform
Alnylam Pharmaceuticals	Outperform Votes 1167 76.32%	Underperform Votes 362 23.68%
Exelixis	Outperform Votes 627 68.60%	Underperform Votes 287 31.40%

Is ALNY or EXEL more profitable?

Exelixis has a net margin of 24.04% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Exelixis' return on equity of 23.52% beat Alnylam Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	-12.37%	N/A	-6.83%
Exelixis	24.04%	23.52%	17.95%

Do analysts prefer ALNY or EXEL?

Alnylam Pharmaceuticals currently has a consensus price target of $319.17, suggesting a potential upside of 9.42%. Exelixis has a consensus price target of $38.94, suggesting a potential downside of 12.22%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.77
Exelixis	2 Sell rating(s)	6 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.47

Summary

Alnylam Pharmaceuticals and Exelixis tied by winning 9 of the 18 factors compared between the two stocks.